Naptumomab estafenatox

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Naptumomab estafenatox
Monoclonal antibody
Type Fab fragment
Source Mouse
Target 5T4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C3255H5025N855O1050S18
Molar mass 73.5 kg/mol
 NYesY (what is this?)  (verify)

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]

Schematic image of naptumomab estafenatox.
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
SAg: superantigen SEA/E-120

Mechanism of action[edit]

Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.

See also[edit]

References[edit]